- Home
- BATRK vs DYN Comparison
BATRK vs DYN Comparison
Compare BATRK & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATRK
- DYN
- Stock Information
- Founded
- BATRK 1991
- DYN 1984
- Country
- BATRK United States
- DYN United States
- Employees
- BATRK N/A
- DYN N/A
- Industry
- BATRK Broadcasting
- DYN Medicinal Chemicals and Botanical Products
- Sector
- BATRK Industrials
- DYN Health Care
- Exchange
- BATRK Nasdaq
- DYN Nasdaq
- Market Cap
- BATRK 2.5B
- DYN 2.6B
- IPO Year
- BATRK N/A
- DYN 2020
- Fundamental
- Price
- BATRK $37.01
- DYN $8.18
- Analyst Decision
- BATRK Strong Buy
- DYN Strong Buy
- Analyst Count
- BATRK 2
- DYN 12
- Target Price
- BATRK $56.50
- DYN $47.73
- AVG Volume (30 Days)
- BATRK 271.3K
- DYN 2.2M
- Earning Date
- BATRK 05-07-2025
- DYN 05-01-2025
- Dividend Yield
- BATRK N/A
- DYN N/A
- EPS Growth
- BATRK N/A
- DYN N/A
- EPS
- BATRK N/A
- DYN N/A
- Revenue
- BATRK $662,748,000.00
- DYN N/A
- Revenue This Year
- BATRK $10.50
- DYN N/A
- Revenue Next Year
- BATRK $7.03
- DYN N/A
- P/E Ratio
- BATRK N/A
- DYN N/A
- Revenue Growth
- BATRK 3.45
- DYN N/A
- 52 Week Low
- BATRK $35.81
- DYN $8.94
- 52 Week High
- BATRK $44.43
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- BATRK 46.56
- DYN 29.09
- Support Level
- BATRK $39.40
- DYN $8.94
- Resistance Level
- BATRK $40.42
- DYN $12.00
- Average True Range (ATR)
- BATRK 0.80
- DYN 0.80
- MACD
- BATRK 0.00
- DYN -0.19
- Stochastic Oscillator
- BATRK 36.65
- DYN 0.77
About BATRK Atlanta Braves Holdings Inc. Series C
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include, baseball which generates key revenue, and mixed-use development.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.